Navigation Links
Amgen's Third Quarter 2013 Revenues Increased 10 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 16 Percent To $1.94
Date:10/22/2013

d Shares (millions)

765783(18)Cash and Investments*

26.525.41.1Debt Outstanding

27.226.50.7Stockholders' Equity

21.719.91.8* 

Includes cash, cash equivalents and marketable securities, receivable from sale of investments, and long-term restricted investmentsNote: Numbers may not add due to rounding2013 Guidance For the full year 2013, the Company expects:

  • Total revenues to be in the range of $18.3 billion to $18.5 billion.
  • Adjusted EPS to be in the range of $7.35 to $7.45.
  • Adjusted tax rate to be in the range of 9 percent to 10 percent, unchanged from previous guidance. Excluding the Puerto Rico excise tax, Amgen expects the adjusted tax rate for 2013 to be in the range of 13 percent to 14 percent.
  • Capital expenditures to be approximately $700 million, unchanged from previous guidance.
  • Third Quarter Pipeline Update The Company provided the following information on selected clinical programs:

    Evolocumab (AMG 145):

  • The Company announced that all of the pivotal lipid lowering studies of evolocumab have completed enrollment and the data are expected in the first quarter of 2014.
  • Trebananib:

  • The Company announced that the primary analysis of the event-driven overall survival secondary endpoint from the ongoing pivotal Phase 3 study in recurrent ovarian cancer (TRINOVA-1) is projected to occur in the second half of 2014.
  • The Company announced that enrollment has been closed in a Phase 3 study in recurrent ovarian cancer (TRINOVA-2) due to DOXIL® (doxorubicin HCl liposome injection) supply issues.
  • Brodalumab:

  • The Company announced that all Phase 3 studies in subjects with psoriasis have completed enrollment and data are expected in 2014.
  • Biosimilars:

  • The Company announced that it has commenced a pivotal study in subjects with psoriasis for its biosimilar Humira® (ad
    '/>"/>

  • SOURCE Amgen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related medicine technology :

    1. Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
    2. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
    3. Pro-Dex, Inc. Announces Fiscal 2012 Third Quarter Financial Results Conference Call and Webcast
    4. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
    5. Cardica Announces Fiscal 2012 Third Quarter Financial Results
    6. Hill-Rom Announces Third Quarter 2012 Dividend
    7. Cardinal Health Reports Third-Quarter Results
    8. TPI to Host Third Quarter of Fiscal Year 2012 Earnings Conference Call on Tuesday, May 15, 2012 at 9:00 a.m. ET
    9. Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results
    10. ThermoGenesis Corp. To Announce Third Quarter Fiscal 2012 Results On May 10, 2012
    11. Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... July 11, 2014  Australian drug delivery company, Phosphagenics ... has raised A$19.3 million via a placement of A$16.3 ... , the U.S., Asia and ... a share purchase plan (SPP) to be offered to ... made in two tranches. "This capital raising ...
    (Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
    (Date:7/10/2014)... , 11. Juli 2014 /PRNewswire/ ... Kameras für die molekulare Bildgebung, einschließlich ... heute die CE-Zulassung für sein Navigator ... kann Dilon das Produkt jetzt europaweit ... den Großteil der europäischen Länder ausgedehnt ...
    Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Veran Medical Publishes Lung Cancer Patient Management Study 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
    ... Sigma-Aldrich Corporation (NASDAQ: SIAL ) will ... KeyBanc Capital Markets 2011 Basic Materials ... InterContinental, Boston, MA, presenting at 9:00 AM (Eastern). ... at the Grand Hyatt, New York, NY, presenting at ...
    ... SimonMed and Cox Business have partnered to make a ... patients in the Valley and across the state at ... is the first dedicated outpatient offering of breast tomosynthesis ... in Scottsdale. Sub-specialty trained radiologists at SimonMed ...
    Cached Medicine Technology:Sigma-Aldrich Corporation to Present at Upcoming Investor Conferences 2SimonMed and Cox Business Bring Breast Tomosynthesis to Arizona 2
    (Date:7/13/2014)... (PRWEB) July 13, 2014 Recently, ... retailer, has unveiled its new range of gorgeous ... current market, the demand for elegant Quinceanera outfits ... more beautiful items. All the company’s newly released ... trends. They are all elegant and vivid. ...
    (Date:7/13/2014)... 13, 2014 Fadhits.com is popular among ... dresses are extremely beautiful. Recently, the company has announced ... for 2014. What’s more, all these outfits are available ... , Additionally, the supplier is now offering similar ... Quinceanera dresses, it has many other designs for sale, ...
    (Date:7/13/2014)... A decreased ability to identify odors might ... disease, while examinations of the eye could indicate ... Alzheimer,s, in the brain, according to the results ... Alzheimer,s Association International Conference 2014 (AAIC 2014) in ... decreased ability to identify odors was significantly associated ...
    (Date:7/13/2014)... 13, 2014 A Xarelto lawsuit ... LLC to provide consumers with the most current information ... of the blood-thinning medication, as well as the ... courts around the country. The law firm is now ... suffered from life-threatening internal bleeding and related complications while ...
    (Date:7/13/2014)... Hope Palliative & Hospice Care announced today ... at the Tamarack Senior Living Community in Palatine, IL. The ... on the 3rd Wednesdays of every month. This group ... Community located at 55 S. Greeley St. Palatine, IL 60067. ... is no cost for the group. , “A grief ...
    Breaking Medicine News(10 mins):Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2
    ... Systems (TSX: LMZ,AMEX: LMZ), a healthcare technology company ... for obstetrics, today announced that its,Board of Directors ... from Amex., The decision is in keeping ... control costs in order to become cash flow,positive. ...
    ... Presentations highlight Palomid 529 as an inhibitor of macular ... ... JAMAICA PLAIN, Mass., May 1 Paloma Pharmaceuticals,Inc. today announced ... the Association for Research in Vision and Ophthalmology (ARVO),describing the ...
    ... The Cosmetic Bootcamp LLC,announced today that its summer ... According to Dr. Kenneth Beer, this year,s meeting is,expected ... meeting has,experienced since its inception four years ago. Dr. ... credibility the meeting has gained with both,physicians and industry. ...
    ... 1 Perrigo Company,(Nasdaq: PRGO ; TASE) ... a,quarterly dividend of $0.05 per share, payable on ... 25, 2008., Perrigo Company is a leading ... (OTC) and prescription,pharmaceuticals, nutritional products, active pharmaceutical ingredients,(API) ...
    ... MedCath Corporation,(Nasdaq: MDTH ) announced that its ... Securities 33rd Annual Health Care,Conference held May 5 - ... management will give its presentation on Wednesday,May 7 at ... live over the,Internet via MedCath,s website ( http://www.medcath.com ) ...
    ... increases 5 percent to $22.9 billion, - GAAP earnings from continuing operations reach $366 million from ... of $5 million in the prior-year period, - GAAP diluted earnings per share from ... from a loss of $0.01 in prior-year period, - Non-GAAP diluted EPS from ... ...
    Cached Medicine News:Health News:LMS to delist from Amex 2Health News:Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting 2Health News:Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting 3Health News:Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting 4Health News:Cardinal Health Reports Third Quarter Results 2Health News:Cardinal Health Reports Third Quarter Results 3Health News:Cardinal Health Reports Third Quarter Results 4Health News:Cardinal Health Reports Third Quarter Results 5Health News:Cardinal Health Reports Third Quarter Results 6Health News:Cardinal Health Reports Third Quarter Results 7Health News:Cardinal Health Reports Third Quarter Results 8Health News:Cardinal Health Reports Third Quarter Results 9Health News:Cardinal Health Reports Third Quarter Results 10Health News:Cardinal Health Reports Third Quarter Results 11Health News:Cardinal Health Reports Third Quarter Results 12Health News:Cardinal Health Reports Third Quarter Results 13Health News:Cardinal Health Reports Third Quarter Results 14Health News:Cardinal Health Reports Third Quarter Results 15Health News:Cardinal Health Reports Third Quarter Results 16Health News:Cardinal Health Reports Third Quarter Results 17Health News:Cardinal Health Reports Third Quarter Results 18Health News:Cardinal Health Reports Third Quarter Results 19Health News:Cardinal Health Reports Third Quarter Results 20Health News:Cardinal Health Reports Third Quarter Results 21Health News:Cardinal Health Reports Third Quarter Results 22Health News:Cardinal Health Reports Third Quarter Results 23Health News:Cardinal Health Reports Third Quarter Results 24Health News:Cardinal Health Reports Third Quarter Results 25Health News:Cardinal Health Reports Third Quarter Results 26Health News:Cardinal Health Reports Third Quarter Results 27Health News:Cardinal Health Reports Third Quarter Results 28Health News:Cardinal Health Reports Third Quarter Results 29Health News:Cardinal Health Reports Third Quarter Results 30Health News:Cardinal Health Reports Third Quarter Results 31
    VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
    VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
    VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
    VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
    Medicine Products: